Related references
Note: Only part of the references are listed.Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer The MA.32 Randomized Clinical Trial
Pamela J. Goodwin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Metformin-induced reductions in tumor growth involves modulation of the gut microbiome
Lindsay A. Broadfield et al.
MOLECULAR METABOLISM (2022)
A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer
Kathy Han et al.
CLINICAL CANCER RESEARCH (2022)
Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer
Youngjoo Lee et al.
LUNG CANCER (2021)
Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer
Michael Skwarski et al.
CLINICAL CANCER RESEARCH (2021)
STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications
Isidora Tosic et al.
NEOPLASIA (2021)
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
Douglas Yee et al.
NPJ BREAST CANCER (2021)
Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
Zhe Fu et al.
CELLS (2021)
TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer
Marc Pujalte Martin et al.
CLINICAL GENITOURINARY CANCER (2021)
Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED)
Reham Alghandour et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)
Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer The NRG-LU001 Phase 2 Randomized Clinical Trial
Heath Skinner et al.
JAMA ONCOLOGY (2021)
Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer The OCOG-ALMERA Randomized Clinical Trial
Theodoros Tsakiridis et al.
JAMA ONCOLOGY (2021)
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial
Pamela J. Goodwin et al.
NPJ BREAST CANCER (2021)
Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer
Shuchi Gulati et al.
CANCER (2020)
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin
Simon R. Lord et al.
BRITISH JOURNAL OF CANCER (2020)
Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer
Benjamin D. Hopkins et al.
NATURE REVIEWS ENDOCRINOLOGY (2020)
Metformin Enhances the Antitumor Activity of CD8+ T Lymphocytes via the AMPK-miR-107-Eomes-PD-1 Pathway
Zhen Zhang et al.
JOURNAL OF IMMUNOLOGY (2020)
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study
V. L. Bae-Jump et al.
GYNECOLOGIC ONCOLOGY (2020)
Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial
Li Li et al.
CLINICAL CANCER RESEARCH (2019)
Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma A Phase 2 Randomized Clinical Trial
Oscar Arrieta et al.
JAMA ONCOLOGY (2019)
Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial
Ya Zheng et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial
O. Nanni et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial
Sarah J. Kitson et al.
CLINICAL CANCER RESEARCH (2019)
A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy
Isabel Pimentel et al.
BREAST (2019)
Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort
Mike M. Nguyen et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2018)
Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer
Lifeng Li et al.
CANCER RESEARCH (2018)
Metformin's antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization
Ji-Chang Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer
Yonathan Lissanu Deribe et al.
NATURE MEDICINE (2018)
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naive Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
Kristen A. Marrone et al.
ONCOLOGIST (2018)
A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin
Matteo Trucco et al.
PEDIATRIC BLOOD & CANCER (2018)
Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer
Simon R. Lord et al.
CELL METABOLISM (2018)
The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial
Susan R. Davis et al.
CLINICAL ENDOCRINOLOGY (2018)
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong-Ho Cha et al.
MOLECULAR CELL (2018)
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Benjamin D. Hopkins et al.
NATURE (2018)
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
Lulu Sun et al.
NATURE MEDICINE (2018)
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
Begoña Martin-Castillo et al.
Oncotarget (2018)
Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome
Ping-Yuan Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Nicole E. Scharping et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Metformin Effects on Head and Neck Squamous Carcinoma Microenvironment: Window of Opportunity Trial
Joseph Curry et al.
LARYNGOSCOPE (2017)
Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-κB signaling
Chi-Fu Chiang et al.
ONCOTARGET (2017)
A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
Yannan Zhao et al.
ONCOTARGET (2017)
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
Vinay Prasad et al.
JAMA INTERNAL MEDICINE (2017)
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial
Michele Reni et al.
CLINICAL CANCER RESEARCH (2016)
Measuring the biological effect of presurgical metformin treatment in endometrial cancer
V. N. Sivalingam et al.
BRITISH JOURNAL OF CANCER (2016)
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
Muhammad R. Khawaja et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Metformin may protect nondiabetic breast cancer women from metastasis
Sahar Mohammed EL-Haggar et al.
CLINICAL & EXPERIMENTAL METASTASIS (2016)
Innovation in the pharmaceutical industry: New estimates of R&D costs
Joseph A. DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2016)
Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial
Takuma Higurashi et al.
LANCET ONCOLOGY (2016)
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
Thomas M. Ashton et al.
NATURE COMMUNICATIONS (2016)
Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial
Sirwan M. Hadad et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Sil Kordes et al.
LANCET ONCOLOGY (2015)
Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer
Kevin M. Schuler et al.
CANCER MEDICINE (2015)
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study
Ryan J. O. Dowling et al.
BREAST CANCER RESEARCH (2015)
Effect of Metformin on Metabolic Improvement and Gut Microbiota
Heetae Lee et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2014)
Effects of Metformin on Endometrial Cancer Cell Growth in Vivo: A Preoperative Prospective Trial
Akira Mitsuhashi et al.
CANCER (2014)
Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer
Kevin Kalinsky et al.
CANCER INVESTIGATION (2014)
Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer
Ido Laskov et al.
GYNECOLOGIC ONCOLOGY (2014)
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides
Kivanc Birsoy et al.
NATURE (2014)
A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer
A. M. Joshua et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2014)
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
William W. Wheaton et al.
ELIFE (2014)
Metformin Enhances Cisplatin Cytotoxicity by Suppressing Signal Transducer and Activator of Transcription-3 Activity Independently of the Liver Kinase B1-AMP-Activated Protein Kinase Pathway
Chien-Chung Lin et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2013)
The effect of metformin on apoptosis in a breast cancer presurgical trial
M. Cazzaniga et al.
BRITISH JOURNAL OF CANCER (2013)
Metformin Decreases Glucose Oxidation and Increases the Dependency of Prostate Cancer Cells on Reductive Glutamine Metabolism
Sarah-Maria Fendt et al.
CANCER RESEARCH (2013)
Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response
Vanessa E. Zannella et al.
CLINICAL CANCER RESEARCH (2013)
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Russell A. Miller et al.
NATURE (2013)
Increased Oxidative Metabolism in the Li-Fraumeni Syndrome
Ping-yuan Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study
Saroj Niraula et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers
Xin-Sheng Deng et al.
CELL CYCLE (2012)
Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial
Bernardo Bonanni et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC
Giovanni Blandino et al.
NATURE COMMUNICATIONS (2012)
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial
Sirwan Hadad et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase
Carolyn Algire et al.
ENDOCRINE-RELATED CANCER (2010)
Metformin suppresses intestinal polyp growth in ApcMin/+ mice
Ayako Tomimoto et al.
CANCER SCIENCE (2008)
AMPK phosphorylation of raptor mediates a metabolic checkpoint
Dana M. Gwinn et al.
MOLECULAR CELL (2008)
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth
Monica Buzzai et al.
CANCER RESEARCH (2007)
Metformin and reduced risk of cancer in diabetic patients
JMM Evans et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2
JE Gunton et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase
PA Lochhead et al.
DIABETES (2000)
Share Paper
